Key clinical point: Median lobe hyperplasia did not interfere with low-dose-rate brachytherapy, but seed migration and degree of cold spots was higher in patients with severe MLH.

Major finding: Migration of iodine-125 seeds occurred in 10 (31.5%) of 32 prostate cancer patients with MLH and 61 (31.6%) of 193 prostate cancer patients without MLH.

Study details: The data come from an analysis of 32 prostate cancer patients with median lobe hyperplasia (MLH) and 193 without MLH; all patients were treated with loose iodine-125 seeds. MLH patients were classified as mild (< 10 mm) or severe (≥ 10 mm) based on the distance between the posterior transitional zone and the prostatic tissue protruding into the bladder.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Muraki K et al. J Contemp Brachytherapy. 2021 Jun 13. doi: 10.5114/jcb.2021.105944.

Key clinical point: Median lobe hyperplasia did not interfere with low-dose-rate brachytherapy, but seed migration and degree of cold spots was higher in patients with severe MLH.

Major finding: Migration of iodine-125 seeds occurred in 10 (31.5%) of 32 prostate cancer patients with MLH and 61 (31.6%) of 193 prostate cancer patients without MLH.

Study details: The data come from an analysis of 32 prostate cancer patients with median lobe hyperplasia (MLH) and 193 without MLH; all patients were treated with loose iodine-125 seeds. MLH patients were classified as mild (< 10 mm) or severe (≥ 10 mm) based on the distance between the posterior transitional zone and the prostatic tissue protruding into the bladder.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Muraki K et al. J Contemp Brachytherapy. 2021 Jun 13. doi: 10.5114/jcb.2021.105944.

Key clinical point: Median lobe hyperplasia did not interfere with low-dose-rate brachytherapy, but seed migration and degree of cold spots was higher in patients with severe MLH.

Major finding: Migration of iodine-125 seeds occurred in 10 (31.5%) of 32 prostate cancer patients with MLH and 61 (31.6%) of 193 prostate cancer patients without MLH.

Study details: The data come from an analysis of 32 prostate cancer patients with median lobe hyperplasia (MLH) and 193 without MLH; all patients were treated with loose iodine-125 seeds. MLH patients were classified as mild (< 10 mm) or severe (≥ 10 mm) based on the distance between the posterior transitional zone and the prostatic tissue protruding into the bladder.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Muraki K et al. J Contemp Brachytherapy. 2021 Jun 13. doi: 10.5114/jcb.2021.105944.

Key clinical point: Approximately half of the studies (16) in a systematic review showed no association between androgen deprivation therapy and reduced cognitive function in prostate cancer patients; however, 11 of the 31 studies showed a negative effect on cognitive functioning.

Major finding: A total of 18 studies used a prospective design to assess the impact of androgen deprivation therapy on cognitive function, totaling 968 individuals. Of these, 9 studies showed no significant effect of ADT on cognitive function.

Study details: The data come from a systematic review of 31 studies published up to February 2020.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Andela CD et al. Int J Urol. 2021 Jun 14.  doi: 10.1111/iju.14596. 

Key clinical point: Approximately half of the studies (16) in a systematic review showed no association between androgen deprivation therapy and reduced cognitive function in prostate cancer patients; however, 11 of the 31 studies showed a negative effect on cognitive functioning.

Major finding: A total of 18 studies used a prospective design to assess the impact of androgen deprivation therapy on cognitive function, totaling 968 individuals. Of these, 9 studies showed no significant effect of ADT on cognitive function.

Study details: The data come from a systematic review of 31 studies published up to February 2020.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Andela CD et al. Int J Urol. 2021 Jun 14.  doi: 10.1111/iju.14596. 

Key clinical point: Approximately half of the studies (16) in a systematic review showed no association between androgen deprivation therapy and reduced cognitive function in prostate cancer patients; however, 11 of the 31 studies showed a negative effect on cognitive functioning.

Major finding: A total of 18 studies used a prospective design to assess the impact of androgen deprivation therapy on cognitive function, totaling 968 individuals. Of these, 9 studies showed no significant effect of ADT on cognitive function.

Study details: The data come from a systematic review of 31 studies published up to February 2020.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Andela CD et al. Int J Urol. 2021 Jun 14.  doi: 10.1111/iju.14596. 

Key clinical point: Transgluteal CT-guided biopsy identified prostate cancer lesions in men without rectal access with no major complications reported.

Major finding: A total of 4 lesions were targeted using anatomic landmarks and 5 were targeted using contrast enhancement. All biopsies using transgluteal CT were technically successful and identified as prostate cancer. A total of 3 biopsies showed Gleason 6 cancer, and 6 biopsies showed clinically significant prostate cancers with Gleason 7 or above; a total of 7 patients underwent definitive treatment with surgery or radiation.

Study details: The data come from a retrospective study of 9 prostate cancer patients without rectal access who underwent transgluteal CT-guided biopsy between May 2016 and February 2021. The two targeting techniques were localizing with anatomic landmarks or localizing with contrast enhancement.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Patel N et al. Clin Imaging. 2021 Jun 9. doi: 10.1016/j.clinimag.2021.06.004.

Key clinical point: Transgluteal CT-guided biopsy identified prostate cancer lesions in men without rectal access with no major complications reported.

Major finding: A total of 4 lesions were targeted using anatomic landmarks and 5 were targeted using contrast enhancement. All biopsies using transgluteal CT were technically successful and identified as prostate cancer. A total of 3 biopsies showed Gleason 6 cancer, and 6 biopsies showed clinically significant prostate cancers with Gleason 7 or above; a total of 7 patients underwent definitive treatment with surgery or radiation.

Study details: The data come from a retrospective study of 9 prostate cancer patients without rectal access who underwent transgluteal CT-guided biopsy between May 2016 and February 2021. The two targeting techniques were localizing with anatomic landmarks or localizing with contrast enhancement.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Patel N et al. Clin Imaging. 2021 Jun 9. doi: 10.1016/j.clinimag.2021.06.004.

Key clinical point: Transgluteal CT-guided biopsy identified prostate cancer lesions in men without rectal access with no major complications reported.

Major finding: A total of 4 lesions were targeted using anatomic landmarks and 5 were targeted using contrast enhancement. All biopsies using transgluteal CT were technically successful and identified as prostate cancer. A total of 3 biopsies showed Gleason 6 cancer, and 6 biopsies showed clinically significant prostate cancers with Gleason 7 or above; a total of 7 patients underwent definitive treatment with surgery or radiation.

Study details: The data come from a retrospective study of 9 prostate cancer patients without rectal access who underwent transgluteal CT-guided biopsy between May 2016 and February 2021. The two targeting techniques were localizing with anatomic landmarks or localizing with contrast enhancement.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Patel N et al. Clin Imaging. 2021 Jun 9. doi: 10.1016/j.clinimag.2021.06.004.

Key clinical point: No significant differences in prostate specific antigen PSA regression, PSA failure rate, and toxicity were noted between the different fraction schedules for patients treated with high-dose-rate mono-brachytherapy.

Major finding: Overall, the biochemical failure rate was 9.6%; biochemical failure rates for the 4F, 3F, and 2F groups 10.5%, 4.7%, and 14.6%, respectively, and 3.5% of patients demonstrated several grade 3-4 toxicity.

Study details: The data come from a retrospective study of 229 adults with prostate cancer treated consecutively at a single center between 2004 and 2012. Patients were treated with high-dose-rate mono-brachytherapy alone, using three different fractionation schedules of 92-95 Gy.

Group 4F had a single implant of 9.5 Gy in four fractions over 2 days. Group 3F had three separate implants of 11 Gy over 4 weeks. Group had two implants of 14 Gy over 2 weeks.

Disclosures: The study was funded by the Örebro County Council. The researchers had no financial conflicts to disclose.

Source: Johansson B et al. J Contemp Brachytherapy. 2021 May 5. doi: 10.5114/jcb.2021.105846. 

Key clinical point: No significant differences in prostate specific antigen PSA regression, PSA failure rate, and toxicity were noted between the different fraction schedules for patients treated with high-dose-rate mono-brachytherapy.

Major finding: Overall, the biochemical failure rate was 9.6%; biochemical failure rates for the 4F, 3F, and 2F groups 10.5%, 4.7%, and 14.6%, respectively, and 3.5% of patients demonstrated several grade 3-4 toxicity.

Study details: The data come from a retrospective study of 229 adults with prostate cancer treated consecutively at a single center between 2004 and 2012. Patients were treated with high-dose-rate mono-brachytherapy alone, using three different fractionation schedules of 92-95 Gy.

Group 4F had a single implant of 9.5 Gy in four fractions over 2 days. Group 3F had three separate implants of 11 Gy over 4 weeks. Group had two implants of 14 Gy over 2 weeks.

Disclosures: The study was funded by the Örebro County Council. The researchers had no financial conflicts to disclose.

Source: Johansson B et al. J Contemp Brachytherapy. 2021 May 5. doi: 10.5114/jcb.2021.105846. 

Key clinical point: No significant differences in prostate specific antigen PSA regression, PSA failure rate, and toxicity were noted between the different fraction schedules for patients treated with high-dose-rate mono-brachytherapy.

Major finding: Overall, the biochemical failure rate was 9.6%; biochemical failure rates for the 4F, 3F, and 2F groups 10.5%, 4.7%, and 14.6%, respectively, and 3.5% of patients demonstrated several grade 3-4 toxicity.

Study details: The data come from a retrospective study of 229 adults with prostate cancer treated consecutively at a single center between 2004 and 2012. Patients were treated with high-dose-rate mono-brachytherapy alone, using three different fractionation schedules of 92-95 Gy.

Group 4F had a single implant of 9.5 Gy in four fractions over 2 days. Group 3F had three separate implants of 11 Gy over 4 weeks. Group had two implants of 14 Gy over 2 weeks.

Disclosures: The study was funded by the Örebro County Council. The researchers had no financial conflicts to disclose.

Source: Johansson B et al. J Contemp Brachytherapy. 2021 May 5. doi: 10.5114/jcb.2021.105846. 

Key clinical point: The immune checkpoint protein B7-H3 expression correlated positively with androgen receptor expression and was associated with biochemical and clinical recurrence in prostate cancer.

Major finding: Researchers identified B7-H3 positivity in 15% of prostate cancer patients in a Spanish cohort and 38% of patients in a Norwegian cohort. B7-H3 expression was significantly associated with biochemical recurrence in the Spanish cohort (P = .003) and with clinical recurrence in the Norwegian cohort (P = .005).

Study details: The data come from an immunohistochemistry analysis of tissue samples from a total of 327 prostate adenocarcinoma patients who underwent radical prostatectomy; 120 from Spain and 206 from Norway.

Disclosures: The study was funded by the Instituto de Salud Carlos III, the Ministerio de Economía y Competitividad, the Research Council of Norway, Marie Skłodowska-Curie Actions, Radiumhospitalets legater, Norway, and UNIFOR-FRIMED legater, Norway. The researchers had no financial conflicts to disclose.

Source: Nunes-Xavier CE et al. Prostate. 2021 Jun 14. doi: 10.1002/pros.24180.

Key clinical point: The immune checkpoint protein B7-H3 expression correlated positively with androgen receptor expression and was associated with biochemical and clinical recurrence in prostate cancer.

Major finding: Researchers identified B7-H3 positivity in 15% of prostate cancer patients in a Spanish cohort and 38% of patients in a Norwegian cohort. B7-H3 expression was significantly associated with biochemical recurrence in the Spanish cohort (P = .003) and with clinical recurrence in the Norwegian cohort (P = .005).

Study details: The data come from an immunohistochemistry analysis of tissue samples from a total of 327 prostate adenocarcinoma patients who underwent radical prostatectomy; 120 from Spain and 206 from Norway.

Disclosures: The study was funded by the Instituto de Salud Carlos III, the Ministerio de Economía y Competitividad, the Research Council of Norway, Marie Skłodowska-Curie Actions, Radiumhospitalets legater, Norway, and UNIFOR-FRIMED legater, Norway. The researchers had no financial conflicts to disclose.

Source: Nunes-Xavier CE et al. Prostate. 2021 Jun 14. doi: 10.1002/pros.24180.

Key clinical point: The immune checkpoint protein B7-H3 expression correlated positively with androgen receptor expression and was associated with biochemical and clinical recurrence in prostate cancer.

Major finding: Researchers identified B7-H3 positivity in 15% of prostate cancer patients in a Spanish cohort and 38% of patients in a Norwegian cohort. B7-H3 expression was significantly associated with biochemical recurrence in the Spanish cohort (P = .003) and with clinical recurrence in the Norwegian cohort (P = .005).

Study details: The data come from an immunohistochemistry analysis of tissue samples from a total of 327 prostate adenocarcinoma patients who underwent radical prostatectomy; 120 from Spain and 206 from Norway.

Disclosures: The study was funded by the Instituto de Salud Carlos III, the Ministerio de Economía y Competitividad, the Research Council of Norway, Marie Skłodowska-Curie Actions, Radiumhospitalets legater, Norway, and UNIFOR-FRIMED legater, Norway. The researchers had no financial conflicts to disclose.

Source: Nunes-Xavier CE et al. Prostate. 2021 Jun 14. doi: 10.1002/pros.24180.

Key clinical point: At 6 months after robot-assisted radical prostatectomy, functional outcomes, but not postoperative complications, were associated with poor scores on quality-of-life assessments.

Major finding: Functional outcomes of urinary incontinence (UI), erectile dysfunction (ED), and urinary complaints (UC) were not significantly associated with post-operative health-related quality of life, but postoperative complications were significantly associated with a slight increase in UC (P < 0.001).

Study details: The data come from an analysis of 528 prostate cancer patients who underwent robot-assisted radical prostatectomy with or without pelvic node dissection between 2012 and 2020.  Patients completed questionnaires about health-related quality of life and functional outcomes.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Hagens MJ et al. J Robotic Surg. 2021 Jun 12. doi: /10.1007/s11701-021-01266-9.

Key clinical point: At 6 months after robot-assisted radical prostatectomy, functional outcomes, but not postoperative complications, were associated with poor scores on quality-of-life assessments.

Major finding: Functional outcomes of urinary incontinence (UI), erectile dysfunction (ED), and urinary complaints (UC) were not significantly associated with post-operative health-related quality of life, but postoperative complications were significantly associated with a slight increase in UC (P < 0.001).

Study details: The data come from an analysis of 528 prostate cancer patients who underwent robot-assisted radical prostatectomy with or without pelvic node dissection between 2012 and 2020.  Patients completed questionnaires about health-related quality of life and functional outcomes.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Hagens MJ et al. J Robotic Surg. 2021 Jun 12. doi: /10.1007/s11701-021-01266-9.

Key clinical point: At 6 months after robot-assisted radical prostatectomy, functional outcomes, but not postoperative complications, were associated with poor scores on quality-of-life assessments.

Major finding: Functional outcomes of urinary incontinence (UI), erectile dysfunction (ED), and urinary complaints (UC) were not significantly associated with post-operative health-related quality of life, but postoperative complications were significantly associated with a slight increase in UC (P < 0.001).

Study details: The data come from an analysis of 528 prostate cancer patients who underwent robot-assisted radical prostatectomy with or without pelvic node dissection between 2012 and 2020.  Patients completed questionnaires about health-related quality of life and functional outcomes.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Hagens MJ et al. J Robotic Surg. 2021 Jun 12. doi: /10.1007/s11701-021-01266-9.

Key clinical point: A risk model based on microRNA expression was superior to preoperative prostate specific antigen and clinical Gleason scores for predicting metastasis and prognosis in prostate cancer patients.

Major finding: Prostate cancer patients with higher scores on the PCa-MRS scale showed significantly lower rates of biochemical recurrence-free survival compared to those with lower scores; the area under the curve for the model was 0.925.

Study details: The data come from an evaluation of urine samples from 149 adults with prostate cancer. The researchers examined levels of circulating microRNAs and identified miR-21, miR-16, miR-142-3p, miR-451, and miR-636 as those associated with metastasis.

Disclosures: The study was funded by the National Research Foundation of Korea. The researchers had no financial conflicts to disclose.

Source: Shin S et al. npj Genom Med. 2021 Jun 11. doi: 10.1038/s41525-021-00212-w.

Key clinical point: A risk model based on microRNA expression was superior to preoperative prostate specific antigen and clinical Gleason scores for predicting metastasis and prognosis in prostate cancer patients.

Major finding: Prostate cancer patients with higher scores on the PCa-MRS scale showed significantly lower rates of biochemical recurrence-free survival compared to those with lower scores; the area under the curve for the model was 0.925.

Study details: The data come from an evaluation of urine samples from 149 adults with prostate cancer. The researchers examined levels of circulating microRNAs and identified miR-21, miR-16, miR-142-3p, miR-451, and miR-636 as those associated with metastasis.

Disclosures: The study was funded by the National Research Foundation of Korea. The researchers had no financial conflicts to disclose.

Source: Shin S et al. npj Genom Med. 2021 Jun 11. doi: 10.1038/s41525-021-00212-w.

Key clinical point: A risk model based on microRNA expression was superior to preoperative prostate specific antigen and clinical Gleason scores for predicting metastasis and prognosis in prostate cancer patients.

Major finding: Prostate cancer patients with higher scores on the PCa-MRS scale showed significantly lower rates of biochemical recurrence-free survival compared to those with lower scores; the area under the curve for the model was 0.925.

Study details: The data come from an evaluation of urine samples from 149 adults with prostate cancer. The researchers examined levels of circulating microRNAs and identified miR-21, miR-16, miR-142-3p, miR-451, and miR-636 as those associated with metastasis.

Disclosures: The study was funded by the National Research Foundation of Korea. The researchers had no financial conflicts to disclose.

Source: Shin S et al. npj Genom Med. 2021 Jun 11. doi: 10.1038/s41525-021-00212-w.

Key clinical point: A risk model based on microRNA expression was superior to preoperative prostate specific antigen and clinical Gleason scores for predicting metastasis and prognosis in prostate cancer patients.

Major finding: Prostate cancer patients with higher scores on the PCa-MRS scale showed significantly lower rates of biochemical recurrence-free survival compared to those with lower scores; the area under the curve for the model was 0.925.

Study details: The data come from an evaluation of urine samples from 149 adults with prostate cancer. The researchers examined levels of circulating microRNAs and identified miR-21, miR-16, miR-142-3p, miR-451, and miR-636 as those associated with metastasis.

Disclosures: The study was funded by the National Research Foundation of Korea. The researchers had no financial conflicts to disclose.

Source: Shin S et al. npj Genom Med. 2021 Jun 11. doi: 10.1038/s41525-021-00212-w.

Key clinical point: A risk model based on microRNA expression was superior to preoperative prostate specific antigen and clinical Gleason scores for predicting metastasis and prognosis in prostate cancer patients.

Major finding: Prostate cancer patients with higher scores on the PCa-MRS scale showed significantly lower rates of biochemical recurrence-free survival compared to those with lower scores; the area under the curve for the model was 0.925.

Study details: The data come from an evaluation of urine samples from 149 adults with prostate cancer. The researchers examined levels of circulating microRNAs and identified miR-21, miR-16, miR-142-3p, miR-451, and miR-636 as those associated with metastasis.

Disclosures: The study was funded by the National Research Foundation of Korea. The researchers had no financial conflicts to disclose.

Source: Shin S et al. npj Genom Med. 2021 Jun 11. doi: 10.1038/s41525-021-00212-w.

Key clinical point: A risk model based on microRNA expression was superior to preoperative prostate specific antigen and clinical Gleason scores for predicting metastasis and prognosis in prostate cancer patients.

Major finding: Prostate cancer patients with higher scores on the PCa-MRS scale showed significantly lower rates of biochemical recurrence-free survival compared to those with lower scores; the area under the curve for the model was 0.925.

Study details: The data come from an evaluation of urine samples from 149 adults with prostate cancer. The researchers examined levels of circulating microRNAs and identified miR-21, miR-16, miR-142-3p, miR-451, and miR-636 as those associated with metastasis.

Disclosures: The study was funded by the National Research Foundation of Korea. The researchers had no financial conflicts to disclose.

Source: Shin S et al. npj Genom Med. 2021 Jun 11. doi: 10.1038/s41525-021-00212-w.

Key clinical point: Gleason scores within grade group 4 prostate cancer were associated with biochemical recurrence, but not cancer-specific mortality or all-cause mortality.

Major finding: Gleason score (GS) 5 + 3 was associated with significantly higher rates of GS upgrading in radical prostatectomy (RP) specimens than either GS 3 + 5 or GS 4 + 4.

Study details: The data come from a retrospective review of 1,791 adults with grade 4 prostate cancer, including 190 with Gleason score (GS) 3 + 5; 1,557 with GS 4 + 4; and 44 with GS 5 + 3).

Disclosures: The study was funded in part by the Medical University of Vienna. The researchers had no financial conflicts to disclose.

Source: Mori K et al. Ann Surg Oncol. 2021 Jun 11. doi: 10.1245/s10434-021-10257-x.

Key clinical point: Gleason scores within grade group 4 prostate cancer were associated with biochemical recurrence, but not cancer-specific mortality or all-cause mortality.

Major finding: Gleason score (GS) 5 + 3 was associated with significantly higher rates of GS upgrading in radical prostatectomy (RP) specimens than either GS 3 + 5 or GS 4 + 4.

Study details: The data come from a retrospective review of 1,791 adults with grade 4 prostate cancer, including 190 with Gleason score (GS) 3 + 5; 1,557 with GS 4 + 4; and 44 with GS 5 + 3).

Disclosures: The study was funded in part by the Medical University of Vienna. The researchers had no financial conflicts to disclose.

Source: Mori K et al. Ann Surg Oncol. 2021 Jun 11. doi: 10.1245/s10434-021-10257-x.

Key clinical point: Gleason scores within grade group 4 prostate cancer were associated with biochemical recurrence, but not cancer-specific mortality or all-cause mortality.

Major finding: Gleason score (GS) 5 + 3 was associated with significantly higher rates of GS upgrading in radical prostatectomy (RP) specimens than either GS 3 + 5 or GS 4 + 4.

Study details: The data come from a retrospective review of 1,791 adults with grade 4 prostate cancer, including 190 with Gleason score (GS) 3 + 5; 1,557 with GS 4 + 4; and 44 with GS 5 + 3).

Disclosures: The study was funded in part by the Medical University of Vienna. The researchers had no financial conflicts to disclose.

Source: Mori K et al. Ann Surg Oncol. 2021 Jun 11. doi: 10.1245/s10434-021-10257-x.

Key clinical point: The Briganti 2019 nomogram accurately predicted lymph node invasion in adults with high-risk, clinically localized prostate cancer.

Major finding: The area under the curve for the Briganti 2019 was 0.71. At a cutoff of 7%, sensitivity, specificity, and negative predictive values were 94.7%, 32.0%a, and 98.8%, respectively.

Study details: The data come from a review of 278 adults with prostate cancer who underwent radical prostatectomy and extended pelvic lymph node dissection. Patients were rated using the Briganti 2019 nomogram; researchers used the area under the curve of the receiver operating characteristic analysis to quantify accuracy.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Fukagawa E et al. Int J Clin Oncol. 2021 Jun 12. doi: 10.1007/s10147-021-01954-4. 

Key clinical point: The Briganti 2019 nomogram accurately predicted lymph node invasion in adults with high-risk, clinically localized prostate cancer.

Major finding: The area under the curve for the Briganti 2019 was 0.71. At a cutoff of 7%, sensitivity, specificity, and negative predictive values were 94.7%, 32.0%a, and 98.8%, respectively.

Study details: The data come from a review of 278 adults with prostate cancer who underwent radical prostatectomy and extended pelvic lymph node dissection. Patients were rated using the Briganti 2019 nomogram; researchers used the area under the curve of the receiver operating characteristic analysis to quantify accuracy.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Fukagawa E et al. Int J Clin Oncol. 2021 Jun 12. doi: 10.1007/s10147-021-01954-4. 

Key clinical point: The Briganti 2019 nomogram accurately predicted lymph node invasion in adults with high-risk, clinically localized prostate cancer.

Major finding: The area under the curve for the Briganti 2019 was 0.71. At a cutoff of 7%, sensitivity, specificity, and negative predictive values were 94.7%, 32.0%a, and 98.8%, respectively.

Study details: The data come from a review of 278 adults with prostate cancer who underwent radical prostatectomy and extended pelvic lymph node dissection. Patients were rated using the Briganti 2019 nomogram; researchers used the area under the curve of the receiver operating characteristic analysis to quantify accuracy.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Fukagawa E et al. Int J Clin Oncol. 2021 Jun 12. doi: 10.1007/s10147-021-01954-4.